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Abstract
Nicotinic acetylcholine receptors (nAChRs) affect multiple
physiological functions in the brain and their functions are
modulated by regulatory proteins of the Lynx family. Here, we
report for the first time a direct interaction of the Lynx protein
LY6/PLAUR domain-containing 6 (Lypd6) with nAChRs in
human brain extracts, identifying Lypd6 as a novel regulator of
nAChR function. Using protein cross-linking and affinity
purification from human temporal cortical extracts, we demon-
strate that Lypd6 is a synaptically enriched membrane-bound
protein that binds to multiple nAChR subtypes in the human
brain. Additionally, soluble recombinant Lypd6 protein atten-
uates nicotine-induced hippocampal inward currents in rat
brain slices and decreases nicotine-induced extracellular
signal-regulated kinase phosphorylation in PC12 cells, sug-
gesting that binding of Lypd6 is sufficient to inhibit nAChR-
mediated intracellular signaling. We further show that perinatal
nicotine exposure in rats (4 mg/kg/day through minipumps to
dams from embryonic day 7 to post-natal day 21) significantly
increases Lypd6 protein levels in the hippocampus in adult-
hood, which did not occur after exposure to nicotine in
adulthood only. Our findings suggest that Lypd6 is a versatile
inhibitor of cholinergic signaling in the brain, and that Lypd6 is
dysregulated by nicotine exposure during early development.
Keywords: affinity purification, Ly-6, LY6/PLAUR domain-
containing 6, Lynx, nicotine.
J. Neurochem. (2016) 138, 806–820.
Members of the Ly-6/neurotoxin (Lynx) superfamily have
been used for decades as lymphocyte differentiation markers
(Bamezai 2004). More recent research has shown that several
Lynx proteins are expressed in the brain [reviewed in (Miwa
et al. 2012)]. Lynx proteins are characterized by a three-
dimensional consensus motif, termed the three-finger fold,
that mediates protein–protein binding (Tsetlin 1999), and
most Lynx proteins are attached on the cell membrane
through a glycosylphosphatidylinositol (GPI) anchor
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(Adermann et al. 1999). The Lynx proteins, Lynx1 and
Lynx2, have been shown to form stable complexes with, and
negatively modulate the response of, a7 and a4b2 nicotinic
acetylcholine receptors (nAChRs) (Miwa et al. 2006; Tek-
inay et al. 2009; Fu et al. 2012). Furthermore, Lynx1
knockout mice exhibit improved associative learning in a
fear-conditioning paradigm (Miwa et al. 2006), and it was
recently shown that Lynx1, acting through nAChRs, is
critical for the loss of synaptic plasticity in the visual cortex
that occurs in adulthood (Morishita et al. 2010). These
results suggest that Lynx1 can bind to and modulate nAChR
function in the brain, and that this has important conse-
quences for synaptic plasticity and memory [reviewed in
(Miwa et al. 2011, 2012; Thomsen and Mikkelsen 2012;
Thomsen et al. 2016)]. However, it is currently not known
whether this regulation of the cholinergic system is unique to
Lynx1 or whether it extends to other members of the Lynx
family.
LY6/PLAUR domain-containing 6 (Lypd6) is a Lynx
protein that is expressed in the human and rodent nervous
system (Darvas et al. 2009; Zhang et al. 2010). In the mouse
visual cortex, Lypd6 and Lynx1 are mainly expressed in
GABAergic interneurons, where they exhibit complementary
expression patterns; the former is exclusively expressed in
somatostatin and the latter is restricted in parvalbumin
interneurons (Demars and Morishita 2014). This implies that
Lypd6 may be involved in modulation of nAChRs in
neuronal circuits distinct from Lynx1. Lypd6 is an important
regulator of embryogenesis in zebrafish through its enhance-
ment of Wnt/b-catenin signaling (€Ozhan et al. 2013), and
Lypd6 knockdown in mice results in small litter size and lack
of ability to procreate, suggesting impaired germ cell or
embryonic development (Darvas et al. 2009). In humans,
two distinct microduplications of the 2q23.1 chromosomal
region containing the Lypd6 gene resulted in severe intel-
lectual disability and autistic features (Chung et al. 2012).
Transgenic over-expression of Lypd6 in mice increases the
Ca2+ component of nicotine-induced currents in dissociated
trigeminal ganglion neurons and results in behaviors indica-
tive of an increased cholinergic tone, such as locomotor
arousal, hypoalgesia, and pre-pulse inhibition of the acoustic
startle response (Darvas et al. 2009). This invites the
possibility that Lypd6, like Lynx1 and Lynx2, modulates
nAChR function by binding to nAChRs. However, to the
best of our knowledge, there is no report of interactions of
Lynx proteins with native nAChRs in the human brain.
Nicotine, the major pharmacologically active chemical
found in tobacco smoke, is another important regulator of the
cholinergic system through its modulation of nAChRs in
animals and humans. Pre- or perinatal exposure to smoking
or nicotine alone can produce long-term alterations in several
transmitter systems including the glutamatergic, serotoner-
gic, and dopaminergic (Wang et al. 2011; Muneoka et al.
1997) and is associated with development of anxiety,
attention deficit hyperactivity disorder, memory deficits,
and other cognitive deficits [reviewed in (Blood-Siegfried
and Rende 2010; Abbott and Winzer-Serhan 2012; Clifford
et al. 2012)].
Here, we report for the first time a direct interaction of
Lypd6 with native human nAChRs from fresh human
temporal cortical extracts and we identify Lypd6 as an
inhibitor of nAChR function in rat hippocampal slices and
PC12 cells. Since Lypd6 and nicotine both modulate
nAChRs and also regulate developmental processes, we
further sought to examine a possible interaction between the
two in a developmental model of nicotine exposure, and
show that nicotine administration to pregnant rats alters
Lypd6 protein levels in the brain of the adult offspring.
Materials and methods
Human tissue and animals
Human temporal neocortical tissue was obtained from an anterior
temporal lobectomy performed in a patient (female, age 58) with
medically intractable temporal lobe epilepsy with hippocampal
onset. Written informed consent was obtained before surgery. The
study was approved by the Ethical Committee in the Capital Region
of Denmark (H-2-2011-104) and performed in accordance with the
Declaration of Helsinki. The tissue was immediately frozen on dry
ice and stored at 80°C until use.
Animal use for brain slice electrophysiology studies (Harlan Mice
laboratories, Denmark) was permitted by the Animal Welfare
Committee, appointed by the Danish Ministry of Justice and all
experiments were in accordance with the institutional guidelines
(The European Communities Council Directive of 24 November
1986 (86/609/EEC) and with Danish laws regulating experiments on
animals.
Pregnant dams and adult male Sprague–Dawley (SD) rats (200–
250 g) were obtained from Charles River Laboratories (Germany),
and housed individually or two per cage, respectively. For the
experiment with perinatal nicotine exposure, timed-pregnant SD rats
were obtained fromHarlan Laboratories (Frederick, MD, USA). Pups
were weaned at post-natal day (PND) 21. Only male pups were
analyzed in this study. Animal procedures were conducted with
approval of the Howard University Animal Care and Use Committee
(HU-IACUC) adhering to the guidelines set forth by the National
Research Council, or in accordance with the Danish National Guide
for Care and Use of Laboratory animals and the European Commu-
nities Council Directive of 24 November 1986 (86/609/EEC).
Mice deficient for the a7 or b2 nAChR subunit (C57BL/6J
background), and wild-type (WT) littermates were purchased from
The Jackson Laboratories and bred at Virginia Commonwealth
University. Mice deficient for the b4 nAChR subunit were obtained
from Baylor University School of Medicine (Xu et al. 1999), and
subsequently maintained at the University of Colorado. Brains from
8 to 12 weeks old male or female homozygous knockout (KO) and
age- and sex-matched wild-type (WT) mice were used.
Animals were kept on a 12/12 h light/dark cycle provided with
standard rodent diet and water ad libitum. The male animals were
acclimatized for a minimum of 7 days and the dams for about 24 h
after arrival before experiments began.
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Developmental, tissue, cellular, and subcellular distribution of
Lypd6
Tissue cross-linking using the cell-impermeable cross-linking agent
bis(sulfosuccinimidyl) suberate (BS3, Pierce Biotechnology), frac-
tionation into crude synaptosomes or soluble and membrane
fractions, culturing of neuronal and astro- and microglia cultures,
as well as the developmental study and sampling of cerebrospinal
fluid has been described previously for the same samples that are
being used in this study (Thomsen et al. 2014a).
mRNA extraction and qPCR
Total RNA was isolated using Trizol Reagent (Sigma-Aldrich,
St. Louis, MO, USA) according to the manufacturer’s instructions.
RNA samples were dissolved in RNase-free water and the RNA
content was quantified using a Nanodrop ND-1000 Spectropho-
tometer (Nanodrop Technologies, Wilmington, DE, USA). Samples
were diluted with RNase-free water to equal RNA concentrations
and reverse transcribed into single-stranded cDNA with Invitro-
genTM SuperScript III First-Strand Synthesis system (Thermo
Fisher Scientific Inc., Waltham, MA, USA) according to the
manufacturer’s directions using 1.25 lM oligo (dT)20 primers,
5 mM MgCl2, and 2 units RNase inhibitor. Real-time qPCR
reactions were performed in a total volume of 20 lL, containing
5 lL sample cDNA, 19 Precision Plus qPCR Master mix, premixed
with SYBR-green (Primerdesign, Southampton, UK), and 16 pmol
of the forward and reverse primers (DNA technology, Aarhus,
Denmark). PCR was performed on a Light Cycler 480 Real-Time
PCR System (Roche, Indianapolis, IN, USA) with a 2-min
preincubation at 95°C followed by 40 cycles of 15 s at 95°C,
10 s at 60°C, and 10 s at 72°C. The primer pair for Lypd6 was
(written 50-30): GCTACAAGATCTGCACCTCC and
GCAAATGTGGCATCAGTGTC. Primer pairs were validated
using serially diluted cDNA to establish a standard curve and by
confirming the existence of a single product on a gel at the correct
molecular weight. Quantification of mRNA expression was per-
formed according to the comparative CT method as described by
Schmittgen and Livak (2008). For each sample, the amount of target
mRNA was normalized to the mean of the PND60 group.
Affinity purification
Recombinant human GST-tagged Lypd6 produced in E.coli (Cus-
abio, Wuhan, China) and dissolved to 1 mg/mL in phosphate-
buffered saline (PBS), pH 7.4 was coupled to PureProteomeTM NHS
Flexibind magnetic beads (Millipore, Billerica, MA, USA) in a ratio
of 1 : 2 (vol/vol) using the manufacturer’s instructions. Successful
coupling was confirmed by subsequent protein determination,
showing a substantial decrease in the protein content of the Lypd6
solution. Another batch of beads without Lypd6 in the PBS was
processed in parallel as a negative control. The beads were
incubated in 0.1% bovine serum albumin in PBS, pH 7.4 for 1 h
at 4°C prior to use.
Approximately, 100 mg human temporal neocortical tissue was
lysed in 1 mL lysis buffer [50 mM Tris, 50 mM NaCl, 5 mM
EDTA, 5 mM EGTA, 10 lL/mL protease inhibitor cocktail (Sigma-
Aldrich, Brøndby, Denmark], pH 7.5) using a PT1200C polytron
blender (Kinematica, Luzern, Switzerland) for 20 s. The lysate was
centrifuged for 30 min at 160 000 g at 20–22°C using an air-driven
ultracentrifuge (Airfuge, Copenhagen, Denmark), and the
supernatant was discarded. The pellet was resuspended in 1 mL
lysis buffer containing 2% Triton X-100 by blending for 20 s and
incubated for 2 h at 4°C on a rotor (15 rpm). Thereafter, the sample
was centrifuged as above and the resulting supernatant (input) was
used for affinity purification. Total protein content was determined
using the Pierce 660 nm Protein Assay (Thermo scientific, Rock-
ford, IL, USA) and 700–1000 lg protein was incubated with 50 lL
magnetic beads in a total volume of 1500 lL lysis buffer for 18–
22 h at 4°C on a rotor (15 rpm). For experiments including a-
bungarotoxin (a-BTX, Tocris Bioscience, Bristol, UK), the tissue
was lysed in 10 ml lysis buffer and centrifugation was performed in
4°C. A quantity of 100 nM a-BTX (final concentration) or vehicle
(PBS) was added to the tissue extracts followed by incubation for
30 min on ice before addition of beads.
Subsequently, a sample of the remaining homogenate after
affinity purification was taken (output) and the beads were washed
twice in 1 M NaCl, 8 mM Na2HPO4, 2 mM NaH2PO4, 0.5% Triton
X-100, pH 7.5, and thrice in 0.1 M NaCl, 8 mM Na2HPO4, 2 mM
NaH2PO4, 0.5% Triton X-100, pH 7.5, and immediately processed
for western blotting.
PC12 cell culture and ERK phosphorylation assay
PC12 cells were maintained in 75 cm2 flasks coated with 5 lg/mL
poly-L-lysine (Sigma-Aldrich), in Dulbecco’s modified Eagle
medium (Gibco Life Technologies, Thermo Fisher Scientific,
Waltham, MA, USA) supplemented with 10% heat-inactivated
horse serum, 5% fetal bovine serum, 25 U/mL penicillin, 25 lg/mL
streptomycin, 1 mM sodium pyruvate, and 2 mM glutamine at 37°C
in a humidified incubator with 5% CO2. Cells were subcul-
tured every 3–4 days by detachment with 0.25% trypsin in EDTA
solution (Gibco Life Technologies) and re-seeded at 15%
confluence.
For the extracellular signal-regulated kinase (ERK) phosphory-
lation assay, cells were seeded in 24-well plates at 12 9 104 cells/
cm2, 24 h prior to the experiment. On the day of the experiment,
cells were incubated for 10 min with recombinant human Lypd6
protein or a-conotoxins PIA, MII, or AuIB (Tocris Bioscience)
diluted in Dulbecco’s modified Eagle medium, followed by 5-min
stimulation with 25 lΜ nicotine (Sigma-Aldrich). Thereafter, cells
were lysed in 100 lL ice cold lysis buffer/well (100 mM NaCl,
25 mM EDTA, 10 mM Tris, 4 mM Na3VO4, 1 mM NaF, and 1%
(v/v) Triton X-100, 1% (v/v) NP-40, 1 lL/mL protease inhibitor
cocktail (Sigma-Aldrich), pH 7.4). Ensure complete lysis, lysates
were then placed in 80°C for 15 min, thawed, and sonicated for
5 s on ice. Lysates were stored at 80°C until use.
Nicotine administration
Nicotine was administered to pregnant rats through a mini-osmotic
infusion pump (Model #2006, Alzet, Cupertino, CA, USA)
surgically implanted between the scapulae at gestational day 7, as
previously described (Wang and Gondre-Lewis 2013; Wang et al.
2011). Nicotine hydrogen tartrate (Sigma-Aldrich, St Louis, MO,
USA) was prepared fresh on the day of pump implantation and
delivered to dams at a rate of 4 mg/kg/day (free base weight) from
pregnancy until pups reached PND21. At PND21, the pups were
weaned and allowed to reach adulthood (PND60). Hippocampus
(HIP) and frontal cortex (FC) from male pups were microdissected
and stored at 80°C for subsequent experimentation. Frontal
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cortical and hippocampal tissue from the left hemisphere were lysed
for western blotting, and hippocampal tissue from the right
hemisphere was used for BS3 cross-linking and synaptosome
preparations as mentioned above. To study the effect of nicotine
when administered directly to young and adult rats, 0.4 mg/kg
nicotine (free base weight) or vehicle (0.9% saline) was adminis-
tered subcutaneously (s.c.) twice daily for 7 days (PND8–14 or 54–
60) and the FC and HIP were dissected 4 h after the last
administration.
Western blotting
Total protein content was measured using a DC Protein Assay Kit
(Bio-Rad, Hercules, CA, USA). Equal amounts of lysates were then
diluted in a loading buffer (final concentration: 60 mM Tris, 10%
(v/v) glycerol, 5% (v/v) mercaptoethanol, 2% (w/v) sodium dodecyl
sulfate, 0.025% (w/v) bromophenol blue, pH 6.8), incubated for
5 min at 95°C, submitted to gel electrophoresis using AnykDTM gels
(Bio-Rad), and blotted onto polyvinylidene difluoride membranes
(Bio-Rad). Membranes were washed in tris-buffered saline with
0.1% Tween 20 (TBS-T) and blocked in TBS containing 5% (w/v)
dry milk powder, which was also used for antibody incubations.
Incubation in primary antisera against Lypd6 (1 : 1000,
#ARP53451_P050, Aviva Systems Biology, San Diego, CA,
USA), Lynx1 (1 : 1000, #sc-23060, Santa Cruz Biotechnology,
Heidelberg, Germany), Ly6H (1 : 1000, #H00004062-M01, Novus
Biologicals, Cambridge, UK), a3, a4, a5, a6 (1 : 100 #sc-1771, sc-
5591, sc-28795, sc-27292 Santa Cruz Biotechnology) for which the
selectivity has been previously characterized (Guan et al. 2001;
Lang et al. 2003; Kabbani et al. 2007; Yu et al. 2007), b2
(1 : 1000, provided by Dr Cecilia Gotti) and a7, b4 (1 : 1000
#ab23832 and 1 : 100 #ab156213 Abcam, Cambridge, UK) which
we have validated in this study (Fig. S3), Actin (1 : 10 000,
#A5060, Sigma-Aldrich), GluR2 (1 : 200, #MABN71, Millipore),
PSD-95 (1 : 2000, #ab9708, Millipore), phosphorylated ERK1/2
(1 : 4000 #9101 Cell Signaling, Leiden, the Netherlands), or ERK1
(1 : 4000, #610031, BD Transduction Laboratories, Franklin Lakes,
NJ, USA) was done overnight at 4°C on parafilm in a humidified
container, followed by 3 9 10 min washes in TBS-T and 1 h
incubation at 20–22°C in horseradish peroxidase-conjugated sec-
ondary antibody (1 : 2000, Dako, Glostrup, Denmark). After
thorough washing in TBS-T, enhanced chemiluminescence western
blotting detection reagents (Western Lightning ECL Pro, Perkin
Elmer, Waltham, MA, USA) were used for signal detection and
protein bands were visualized using an automated film developer
(Colenta Labortechnik, Wiener Neustadt, Austria). Mean optical
densities of bands were measured and their corresponding back-
ground measurement subtracted.
Brain slice preparation and electrophysiology
Patch clamp, whole-cell recordings were made from hippocampal
CA1 interneurons in rat brain slices to determine the effects of
Lypd6 on membrane current responses to nAChR agonists.
Preparation of brain slices containing hippocampal CA1 neurons
was conducted essentially as previously described (Soni and
Kohlmeier 2016). Briefly, 12- to 15-day-old Naval Medical
Research Institute (NMRI) wild-type mice of either sex were
anesthetized with isoflurane, decapitated, and the brain was rapidly
removed and placed into an ice-cold (0–4°C) artificial cerebrospinal
fluid (ACSF) which contained (in mM): 124 NaCl, 5 KCl, 1.2
Na2HPO4, 2.7 CaCl2, 1.2 MgSO4, 10 glucose, and 2.6 NaHCO3,
bubbled with 95% O2/5% CO2 resulting in a pH of 7.4. The block of
the brain containing the HIP was sectioned into 250-lm thick
coronal slices using a vibrotome (Leica VT 1200S, Leica, Germany)
after vertical deflection was minimized. Thereafter, slices containing
the HIP were incubated in ACSF at 37°C for ̴ 20 min followed by
maintenance at 20–25C for 1 h to reach equilibration.
All recordings were conducted in a submersion recording
chamber at 20–25C. Whole-cell recordings were obtained from
CA1 interneurons, identified visually using an upright microscope
(Olympus BX51WI, Hamburg, Germany). Recording pipettes were
made from borosilicate glass capillary tubing (1.5 mm O.D), pulled
on a horizontal puller (Sutter Instruments, P-95) and filled with
internal patch solution (resistance of ̴ 6 MΏ) containing: (in mM)
144 K gluconate, 3 MgCl2, 10 HEPES, 0.3 NaGTP, and 4 Na2ATP
(295–300 mOsM). Membrane currents were recorded using
an Axopatch-200B amplifier (Axon Instruments) and were filtered
at 2 KHz (low-pass Bessel filter) at the amplifier output and digitized
at 20 KHz, with subsequent analysis of current amplitudes
performed with Clampex 10.3 (Molecular Devices, Sunnyvale,
CA, USA).
Membrane responses induced by the activation of nAChRs on
CA1 interneurons were recorded following application of nicotine
(100 lM, Sigma, St. Louis, MO, USA), or the nAChR agonist,
Dimethylphenylpiperazinium (DMPP) (50 mM, Sigma), in the
absence or presence of human recombinant Lypd6 protein (6 lM,
Cusabio). All agonists were applied from borosilicate micropipettes
( ̴ 2 MΩ) using pressure delivered via a picospritzer III (Parker
Hannifin Corporation, Mayfield Heights, OH, USA) at a distance of
≤ 100 lm from the recorded soma, with a constant pressure
maintained at 10 psi for 10–50 ms. Lypd6 was also applied using
a borosilicate micropipette ( ̴ 500 KΩ) using pressure delivered via a
picospritzer III at a distance of ̴ 200 lm from recorded somas, with a
constant pressure maintained at 10 psi for a duration of 4–5 s.
During Lypd6 application, bath perfusion of ACSF was stopped for
3–4 min in order to maximize the diffusion of Lypd6 into the slice.
To check the specificity of Lypd6-dependent effects on nAChR
responses, the order of drug application was reversed in a few
recordings, such that slices were exposed to Lypd6, then nAChR
agonists were applied.
Statistical analysis
Data were analyzed using two-way ANOVA with Sidak-corrected
multiple comparisons or Bonferroni-corrected ratio paired t-tests.
For the electrophysiological recordings, data were analyzed using
unpaired or paired t-tests. The statistical calculations were per-
formed using GraphPad Prism version 6 for Windows (GraphPad
Software, San Diego, CA, USA). All data are presented as
mean  standard error of the mean, and a p-value of < 0.05 was
considered statistically significant.
Results
Distribution and developmental expression of Lypd6
To characterize the expression pattern of Lypd6, we analyzed
Lypd6 protein levels in different organs of adult male rats
using western blotting. A band corresponding to Lypd6
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protein was detected in all organs analyzed with high levels
in the cortex and cerebellum of the brain, moderate levels in
the lung, kidney, and liver, and low levels in the heart and
prostate (Fig. 1a). In the kidney, the Lypd6 antibody
detected an additional lower molecular weight band.
Wefurtherdetectedhigh levelsof endogenousLypd6protein
in rat primary cortical neurons cultured to 14 DIV (Fig. 1b).
Cortical neurons cultured to 7 DIV and astroglia cultured to
18 DIV displayed moderate staining, whereas Lypd6 was not
detectable in primary microglia cultured to 15 DIV.
Previous studies have shown that Lynx proteins are not
only expressed as GPI-anchored membrane proteins but may
also exist as soluble proteins (Adermann et al. 1999;
Bamezai 2004). Fractionation of rat cortical tissue into
soluble and membrane fractions by ultracentrifugation and
subsequent western blotting alongside samples of rat cere-
brospinal fluid (CSF) revealed that Lypd6 was detectable in
the membrane fraction, but not in the soluble fraction or in
CSF samples (Fig. 1c). To validate the separation, we
demonstrated that the membrane-associated scaffolding
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Fig. 1 Distribution and developmental expression of Lypd6. (a–e)
Representative images and analysis of western blots showing Lypd6
protein levels in: (a) different organs of adult male rats (n = 2) in
relation to actin, (b) cortical tissue from adult male rats, rat cortical
primary neurons cultured for 7 or 14 days in vitro (neuron DIV7 and 14,
respectively), rat primary microglia cultured for 15 days in vitro, and rat
primary astroglia cultured for 18 days in vitro (n = 3) in relation to actin,
(c) cerebrospinal fluid (CSF), and soluble and membrane fractions of
cortical tissue from adult male rats. The membrane-bound proteins,
PSD-95 and GluR2, and the soluble protein extracellular signal-
regulated kinase 1 (ERK) are used as controls for effective fraction-
ation (n = 4), (d) FC and HIP tissue fractionated using differential
centrifugation into a pellet 1 (P1, nuclear) and pellet 2 (P2, crude
synaptosome) fraction. Data are normalized to actin levels and the
level of the non-fractionated homogenate (Hom) was set to 1 (dashed
line). *p < 0.05, **p < 0.01 indicates statistical difference between
non-fractionated homogenate and the P2 fraction, #p < 0.05 indicates
statistical difference between the P1 and P2 fractions in a Bonferroni-
corrected ratio paired t-test (n = 5), (e) minced tissue extracts from the
FC or HIP of adult male rats cross-linked with bis(sulfosuccinimidyl)
suberate (BS3) or vehicle (Veh). The staining for GluR2 shows that
cross-linking with BS3 reduces the intensity of the GluR2 band at 95
kDa, and produces a smear of high-molecular weight cross-linked
proteins. Data are normalized to actin levels and the vehicle group was
set to 1. **p < 0.01, ***p < 0.001 indicates statistical difference
between vehicle- and BS3-treated tissue in a Bonferroni-corrected
ratio paired t-test (n = 9–11). (f) Lypd6 mRNA levels in frontal cortex
(FC) and hippocampus (HIP) from male rats killed at post-natal day 1,
7, 14, 26, 42, or 60 (n = 5–6). The values were normalized to GAPDH
levels.
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protein, post-synaptic density 95 (PSD-95), and the a-amino-
3-hydroxy-5-methylisoxazole-4-propionate receptor subunit
GluR2 were only present in the membrane fraction, whereas
the soluble protein ERK1 was only present in the soluble
fraction.
To determine the subcellular localization of Lypd6, tissue
homogenates from the FC and HIP were fractionated into
nuclear (P1) and synaptosomal (P2) fractions (Fig. 1d).
There was a significantly higher level of Lypd6 in the HIP
synaptosomal fraction compared to the total homogenate
(p < 0.01). Additionally, comparing the synaptosomal and
nuclear/endosomal fractions revealed a significantly higher
level of Lypd6 in synaptosomes in both the FC and HIP
(both p < 0.05). GluR2 was used as a positive control as it is
known to be located in the synaptosomal fraction (Srivastava
et al. 1998).
To determine the extent of surface expression of Lypd6,
protein levels in tissue extracts from the FC or HIP of adult
rats, cross-linked using the cell-impermeable protein cross-
linking agent BS3, were compared with untreated extracts
(Fig. 1e), and the GluR2 receptor subunit was used as a
positive control and reference value (Grosshans et al. 2002;
Mielke and Mealing 2009; Carino et al. 2012). In the HIP,
the Lypd6 signal was reduced by 42  0.07%
(mean  SEM, p < 0.01) compared to non-cross-linked
tissue extracts, corresponding to 87% of the signal reduction
seen with GluR2, showing that Lypd6 is predominantly
present on the cell surface. In the FC, the Lypd6 signal was
reduced by 24  0.11%, but was not significantly different
from vehicle controls.
We finally studied the expression pattern of Lypd6 during
development. We measured Lypd6 mRNA levels in the FC
and HIP of rats at PND1, 7, 14, 26, 42, and 60 (Fig. 1f).
Lypd6 mRNA was present in the FC at birth, but decreased
to PND26 with a slower decrease from PND26 until PND60.
In the hippocampal formation, Lypd6 mRNA was detected at
high levels at birth and the levels decreased to near adult
levels within the first three post-natal weeks.
Taken together, these data indicate that Lypd6 is a
membrane-bound protein, predominantly expressed in the
rodent brain and highly enriched at the synaptic loci.
Lypd6 binds to multiple nAChRs in human brain extracts
Members of the Lynx family have been demonstrated to bind
to nAChRs altering their function (Iba~nez-Tallon et al. 2002;
Tekinay et al. 2009; Jensen et al. 2015). To test the binding
of Lypd6 for nAChR subunits, we performed affinity
purification using bead-coupled recombinant human Lypd6
as bait. In extracts from human temporal cortex, Lypd6 was
co-purified with a3, a4, a5, a6, a7, b2, and b4 nAChR
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Fig. 2 Lypd6 binds multiple nAChR subunits in the human brain. (a)
Cortical homogenates from human temporal cortex (input) were
affinity purified using magnetic beads covalently coupled with
recombinant human Lypd6 (Lypd6) or non-coupled beads (ctrl). Also
shown is the remaining homogenate after affinity purification (output).
Samples were submitted to gel electrophoresis and western blotting
followed by detection of nAChR subunits and the GluR2 AMPA
receptor subunit. (b) Representative images of western blots of Lypd6
affinity purification of human temporal cortex homogenates pre-
incubated with 100 nM a-BTX or vehicle [phosphate-buffered saline
(PBS)] for 30 min. (c) Quantification of data represented in (b),
showing that a-BTX interferes with binding of the a7 nAChR subunit
to Lypd6-coupled beads (n = 5). Values are normalized to their
individual vehicle and represented as mean  SEM. **p < 0.01
indicates statistical difference from affinity purification in the absence
of a-BTX in a ratio paired t-test.
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subunits (Fig. 2a), but not with GluR2. None of the nAChR
subunits were detected when the affinity purification was
performed using non-coupled beads, confirming that co-
purification of nAChR subunits was attributable to a specific
interaction with Lypd6. The selectivity of a7, b2, and b4
nAChR subunit antibodies used was verified by performing
affinity purification with human recombinant Lypd6-coupled
beads on a7, b2, and b4 KO mice cortical tissue, showing
that each of the subunits was only detected in the
corresponding WT, but not KO homogenates (Fig. S3).
Although quantitative assessment is not possible because of a
low sample number, visual comparison of the input and
output homogenates from the affinity purification suggest a
reduction in band intensity for a4, a6, and a7, indicating that
a detectable proportion of these nAChR subunits have been
co-purified by Lypd6.
Pre-incubation of human temporal cortical extracts with
the a7-specific orthosteric antagonist a-BTX (100 nM)
significantly reduced the amount of the a7 nAChR subunit
(26.8  0.04%, p < 0.01) isolated during the Lypd6 affinity
purification compared to pre-incubation with PBS, whereas it
did not significantly affect the amount of a3, a4, a5, a6, b2,
or b4 purified (Fig. 2b and c). These results suggest that
Lypd6 is able to interact with several nAChR subunits in the
human cortex, and that Lypd6 competes with a-BTX for
binding to the a7 nAChR.
Lypd6 regulates nicotine-induced ERK phosphorylation
To further assess the functional effect of Lypd6 binding to
nAChRs, we used rat pheochromocytoma PC12 cells that
natively express nAChRs (Nakayama et al. 2006). Stimula-
tion with 25 lM nicotine significantly increased phosphory-
lation of the MAP kinase ERK in PC12 cells. This increase
was completely inhibited by pre-incubation with 4 lM
recombinant human Lypd6 (Fig. 3). Lower concentrations
of recombinant Lypd6 (0.04 and 0.4 lM) also slightly
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Fig. 3 Lypd6 inhibits nicotine-induced ERK phosphorylation. (a) Pre-
incubation for 10 min with 4 lM recombinant human Lypd6 reduces
nicotine-induced ERK phosphorylation in PC12 cells, after stimulation
with 25 lM nicotine for 5 min. (b) Representative images of a western
blot membrane summarized in (a), where the phosphorylated isoforms
p44 and p42 of the MAP kinase ERK (ERK1/2) are represented in the
top panel (pERK), whereas the total amount of unphosphorylated ERK
1/2 is indicated in the bottom panel (totERK). **p < 0.01, ***p < 0.001
indicates statistical difference from the nicotine group in a one-way
ANOVA test.
Fig. 4 Lypd6 reversibly attenuates nAChR-induced membrane
responses in CA1 hippocampal interneurons. (a) Bright field image
of the stratum radiatum of the CA1 hippocampal region where
recordings were conducted (white arrow indicates recorded cell).
Lypd6 (6 lM) was applied via a 2nd patch pipette (black arrow) close
to the recorded cell and nicotine was applied via a 3rd pipette (gray
arrow). Higher magnification image of a CA1 interneuron recorded for
this study (white arrow). The electrode delivering nicotine is also visible
(gray arrow). (b) Whole-cell voltage clamp recordings from a CA1
interneuron showing no effect on induction of inward current by
application of Lypd6. (c) An example of whole-cell voltage clamp
recordings from a CA1 interneuron showing induction of inward current
by application of nicotine (arrow) and attenuation of this current when
applied in the presence of Lypd6 (Nic + Lypd6). Nicotine responses
were not attenuated with a 3-min interval between applications,
indicating that reductions induced in the presence of Lypd6 were not
because of cell run down, but were specific to the presence of the
protein. (d) An example of whole-cell voltage clamp recordings from a
CA1 interneuron, pre-incubated in Lypd6 for 5 min before first
application of nicotine, showing that the effect of Lypd6 is lost upon
wash-out. The recording examples shown in (c) and (d) are not
representing the mean values, but were rather chosen as high-
amplitude samples to clearly demonstrate the inhibitory effect of
Lypd6. (e) Graphs of mean responses to nicotine (ncells = 5) and to the
non-subtype-specific nAChR agonist DMPP (ncells = 3) from the
population of cells recorded, indicating that when Lypd6 is present,
the amplitude of inward currents induced by activation of nAChRs is
significantly reduced. Data are displayed as each cell’s response to the
agonist in the presence of Lypd6 normalized to the same cell’s
response before the addition of Lypd6. Values are represented as
mean  SEM. *p < 0.05, **p < 0.01, indicates statistical difference
between groups in a paired t-test.
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reduced ERK phosphorylation, but this did not reach
significance. Lypd6 exposure alone did not affect basal
levels of ERK phosphorylation. We have previously shown
that the effect of nicotine on ERK phosphorylation in the
PC12 cell line we used here is dependent on a3b4-containing
nAChRs (Arvaniti et al. 2015).
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Lypd6 attenuates nicotine-induced hippocampal inward
currents
Whole-cell recordings were obtained from visually identified
hippocampal CA1 interneurons (Freund and Buzsaki 1996;
Alkondon and Albuquerque 2001) of stratum oriens and
stratum radiatum, where these interneurons have horizontally
oriented spindle-shaped cell bodies and this feature is charac-
teristically distinct from pyramidal neurons (Fig. 4a). Hip-
pocampal interneurons where chosen because of the abundant
expression of the a7 nAChR subtype (Frazier et al. 1998;
Buhler and Dunwiddie 2001, 2002).
Lypd6, when applied alone, did not induce an outward or
inward membrane current (Fig. 4b). When held at 60 mV,
nicotine application (100 lM, 10–50 ms duration) resulted
in an inward current of 67.2  22.0 pA, which was
repeatable with an interval of at least 3 min between nicotine
applications (n = 5, Fig. 4c and d). In the presence of Lypd6
(6 lM), the average reduction in nicotine-induced inward
currents in each individual neuron was 57.4  15.2%
(mean  SEM, paired t-test, p < 0.01, ncells = 5, Fig. 4e).
Similarly, the non-specific nAChR agonist, DMPP (50 lM)
induced an average inward current of 29.7  7.2 pA, which
was attenuated by 74.8  12.6% when DMPP was applied
in the presence of Lypd6 (ncells = 3, t-test, p < 0.05;
Fig. 4e).
We further examined whether Lypd6-mediated attenuation
of inward currents was because of order effects, or run down
of nAChR responses because of cellular exhaustion. After
pre-incubation with Lypd6, nicotine was applied repeatedly,
with a recovery time in between applications of ~ 3 min
(Fig. 4d). A gradual increase in the amplitude of nicotine-
induced inward currents was noted, suggesting that the
observed effect was associated only with the presence of
Lypd6 and could be reversed.
(a) (b)
(c) (d)
Fig. 5 Perinatal nicotine exposure increases hippocampal Lypd6
levels. (a) Quantification of Lypd6, Lynx1, and Ly6H protein levels
as well as the b2 nAChR subunit from frontal cortex (FC) and
hippocampus (HIP) of male rats exposed to nicotine from embryonic
day 7 to post-natal day (PND) 21 through osmotic minipumps
implanted into pregnant dams. Animals were killed at PND7 (n = 5),
21 (n = 10), or 60 (n = 13). Main effect of nicotine treatment in a two-
way ANOVA with age and treatment as the fixed factors is indicated in
the graphs. *p < 0.05 indicates statistical difference in a Sidak-
corrected multiple comparisons test. (b) Representative western blot
images of protein levels from FC and HIP at the different ages. (c)
Quantification of Lypd6 and GluR2 protein levels in hippocampal
tissue from the P60 groups described (a), showing that perinatal
nicotine exposure increases hippocampal Lypd6 levels in nuclear/
endosomal fractions. Tissue was fractionated using differential cen-
trifugation into a pellet 1 (P1, nuclear) and pellet 2 (P2, crude
synaptosome) fraction or cross-linked with bis(sulfosuccinimidyl)
suberate (BS3). Data are normalized to actin levels and the level of
the untreated, non-fractionated homogenate was set to 1 (dashed
line). *p < 0.05, **p < 0.01, ***p < 0.001 indicates statistical differ-
ence from homogenate in a ratio paired t-test, #p < 0.05 indicates
statistical difference between vehicle- and nicotine-treated groups in
an unpaired t-test. (d) Representative western blot images of protein
levels shown in (c).
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Perinatal nicotine exposure increases Lypd6 levels
We analyzed the protein levels of Lypd6, Lynx1, and
Ly6H at PND7, 21, and 60 in the FC and HIP of male
rats exposed to continuous infusion of nicotine via
osmotic minipumps implanted into the pregnant dams
(Fig. 5a and b).
A two-way ANOVA with age and treatment as the fixed
factors revealed a significant main effect of nicotine
treatment on Lypd6 levels in the HIP (p < 0.01), but did
not reach significance in the FC (p = 0.07). A subsequent
Sidak-corrected multiple comparison on HIP samples
showed that nicotine significantly increased Lypd6 levels at
PND60 (Fig. 5a). A main effect of nicotine was also
demonstrated on b2 levels in the FC (p < 0.01), where a
multiple comparisons test showed a significant effect of
nicotine on b2 levels at PND21. Two-way ANOVAs on Lynx1
or Ly6H levels showed no significant main effect of nicotine.
To further characterize the effect of nicotine on hippocam-
pal Lypd6 levels, we demonstrate that nicotine administra-
tion significantly increased Lypd6 levels in the putative
nuclear fraction (P1, p < 0.05), whereas there was no
difference between the groups in synaptosomal fractions
(P2) or on Lypd6 surface levels, as measured using BS3
cross-linking of proteins (Fig. 5c). To validate the methods,
we show that GluR2 is reduced by cross-linking and
increased in synaptosomes in the two groups. Administration
of nicotine (0.4 mg/kg s.c. twice daily for 7 days) to young
or adult rats, did not alter protein levels of Lypd6, Lynx1, or
Ly6H in the FC or HIP (Fig. 6).
Moreover, Lypd6, Lynx1, and Ly6H protein levels in FC
from wild-type and b2, a7, or b4 knockout mice were
compared using unpaired t-tests. No significant differences
were found after genetic deletion of these nAChR subunits
(Fig. 7).
Discussion
Here, we show that recombinant Lypd6 binds to multiple
nAChR subunits in the human brain and inhibits nicotine-
mediated activation of nAChRs in vitro. Furthermore, perina-
tal nicotine administration leads to increased hippocampal
Lypd6 protein levels in adulthood. These results suggest that
Lypd6 modifies cholinergic neurotransmission by a direct
interaction with mature nAChRs in the brain, and that this
regulation may be altered by maternal exposure to nicotine.
Lypd6 is situated to regulate neurotransmission in the brain
Lypd6 protein was detectable in all organs examined and had
a high expression in the brain. The ubiquitous expression of
Lypd6 protein is in accordance with Lypd6 mRNA
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Fig. 6 Short-term nicotine exposure does not alter Lypd6, Lynx1, or
Ly6H levels in the brain. Lypd6, Lynx1, Ly6H, and b2 nAChR subunit
protein levels were analyzed in (a) frontal cortex (FC) and hippocampal
(HIP) tissue from rats administered nicotine (0.4 mg/kg s.c., twice
daily) or vehicle (0.9% saline) for 7 days from day 8–14 or (b) 54–60
(n = 8). (c and d) Representative images of western blots summarized
in (a) and (b), respectively.
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expression in human and mouse organs (Darvas et al. 2009;
Zhang et al. 2010). In primary cultures, Lypd6 is expressed
by neurons and astroglia, but not by microglia. We have
previously demonstrated that the Lynx proteins, Lynx1 and
Ly6H, are exclusively expressed in neurons (Thomsen et al.
2014a), but other Lynx proteins have also been detected in
glia (Cray et al. 1990; Rogers et al. 1996; Tanaka et al.
1997; Mildner et al. 2007).
Lynx proteins may exist as GPI-anchored membrane
proteins or soluble proteins (Adermann et al. 1999; Bamezai
2004). We detected Lypd6 in membrane fractions, but not
soluble fractions or CSF samples and found that Lypd6 was
predominantly localized to synaptosomes in the rat cortex,
suggesting that Lypd6 is a membrane protein involved in
synaptic function. This is in line with in silico analysis of the
Lypd6 gene in zebrafish, showing that it contains a possible
GPI-attachment site, as well as studies in both zebrafish
embryos and a mammalian cell line, showing that Lypd6 is
GPI-anchored on the cell membrane (€Ozhan et al. 2013). In
contrast, other members of the Lynx family such as the
prostate stem cell antigen are detected only in the soluble
fraction (Jensen et al. 2015). This discrimination may
underlie differences in the mode of action, as a soluble
version of the Lynx protein Lynx1 has been shown to exert a
distinctive phenotype compared to the full-length form,
when expressed in a transgenic mouse model (Miwa and
Walz 2012).
We further found that Lypd6 mRNA is highly expressed
during early development, showing high levels in the first
post-natal days in rat FC and HIP, followed by a decrease
toward adulthood. Our results imply a potential crucial role
for Lypd6 in early mammalian development and support
previous data, showing Lypd6 to be essential in vertebrate
embryogenesis, by being involved in mesoderm and
neuroectoderm patterning in zebrafish gastrulation (€Ozhan
et al. 2013). In addition, the developmental expression
pattern of several other Lynx proteins in the brain, such as
Lynx1, Lynx2, or Ly6H, as well as the involvement of
Lynx1 in the regulation of plasticity in the visual cortex
further support a role of this protein family in development
(Dessaud et al. 2006; Morishita et al. 2010; Thomsen et al.
2014a).
Lypd6 binds to and regulates nAChRs
We detected co-purification of a3, a4, a5, a6, a7, b2, and b4
nAChR subunits by affinity pull-down from human cortical
extracts, using recombinant human Lypd6. This is the first
demonstration of a direct interaction between a Lynx protein
and native nAChRs in the human brain. These data indicate
that Lypd6 protein is able to bind to multiple nAChR
subunits in the human brain, including the clinically relevant
a7 nAChR [reviewed in (Thomsen and Mikkelsen 2012)].
We have previously shown that a soluble version of Lynx1
also binds multiple nAChR subunits (Thomsen et al. 2014b),
but this broad spectrum of binding is not a feature of all Lynx
proteins, as SLURP-1 has been shown, using the same
method, to bind selectively to a7 nAChRs (Lyukmanova
et al. 2016).
To specifically investigate the interaction between Lypd6
and the human a7 nAChR, we used a-BTX and showed that
it can interfere with a7 binding to Lypd6. This suggests that
Lypd6 binds orthosterically to a7 nAChRs, although we
cannot exclude the possibility that binding of a-BTX leads to
conformational changes on the a7 nAChR, changing its
affinity for Lypd6. If indeed Lypd6 binds on the orthosteric
site, it indicates that Lypd6 could act as an antagonist, rather
than an allosteric modulator, of nAChR function. In contrast,
Lynx1 does not compete with a-BTX for binding to human
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Fig. 7 Knockout of nAChR subunits does not alter Lypd6, Lynx1, or
Ly6H levels in frontal cortex. Quantification of Lypd6, Lynx1, and Ly6H
protein levels from FC of mice that were either wild-type (WT) or had a
genetic deletion knockout (KO) of the b2 (n = 7–8), a7 (n = 7–8), or b4
(n = 4) nAChR subunit gene. Data are normalized to actin levels and
the level of the respective WT was set to 1. Unpaired t-tests revealed
no significant differences between WT and KO mice.
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a7 nAChRs or with epibatidine for binding to a4b2 nAChRs,
suggesting that it binds outside of the orthosteric binding site
(Lyukmanova et al. 2011).
The direct binding between Lypd6 and nAChRs prompted
us to ask whether this had an effect on nAChR function. We
show that a soluble version of Lypd6 completely inhibits
nicotine-induced phosphorylation of ERK in PC12 cells and
reversibly attenuates nicotine-induced inward currents in
hippocampal interneurons of rat brain slices. This is in line
with previous studies, indicating a modulatory role of Lynx
proteins on whole-cell currents (Miwa et al. 1999; Iba~nez-
Tallon et al. 2002; Puddifoot et al. 2015; Wu et al. 2015;
Lyukmanova et al. 2016). Notably, Lypd6 exposure did not
affect the baseline membrane current or basal levels of ERK
phosphorylation, suggesting that the inhibitory effect is
specifically related to nAChR signaling and that Lypd6 is not
able to activate nAChRs. Activation of the ERK/MAPK
pathway by phosphorylation is an important step in the
formation of Long-term potentiation (LTP) and memory in
the HIP (Adams and Sweatt 2002), and nicotine-mediated
enhancement of LTP in the HIP is dependent on ERK
(Welsby et al. 2009). In accordance with previous findings
(Nakayama et al. 2006), we have shown that this effect of
nicotine in PC12 cells is dependent on a3b4-containing
nAChRs (Arvaniti et al. 2015), suggesting that Lypd6 affects
the function of a3b4-containing nAChRs. This is not to say,
however, that the effects of Lypd6 in the brain are restricted
to a3b4-containing nAChRs.
Our results suggest that Lypd6 can act as an endogenous
orthosteric antagonist of nAChRs in the brain. This sets
Lypd6 aside from other Lynx proteins, such as Lynx1 and
Lynx2, which have been shown to bind to and negatively
regulate the function of a7 and a4b2 nAChRs in heterolo-
gous expression systems (Iba~nez-Tallon et al. 2002; Tekinay
et al. 2009), suggesting an allosteric mode of action.
However, we have employed a soluble variant of Lypd6
that could possibly function differently than, or bind to sites
otherwise unreachable by, endogenous GPI-anchored Lypd6
on nAChRs, as previously speculated for the soluble Lynx1
protein (Miwa and Walz 2012).
It has previously been shown that transgenic over-
expression of Lypd6 in mice increases nicotine-induced
calcium currents and enhances behaviors associated with
cholinergic neurotransmission (Darvas et al. 2009). Our
finding that Lypd6 forms a stable complex with nAChRs
suggests that these effects may be caused by a direct
interaction between Lypd6 and nAChRs. The apparent
discrepancy between an enhancement of calcium currents
and a decrease in inward currents and phosphorylation of
ERK by Lypd6 may be explained by the experimental setups.
We have employed a short exposure to a soluble variant of
Lypd6, which likely affects primarily surface nAChRs, and
which might bind differently to nAChRs compared with
endogenous Lypd6. Transgenic over-expression of Lypd6,
on the other hand, may have more complex effects, possibly
involving chaperoning of nAChRs by Lypd6 in the endo-
plasmic reticulum, as has previously been demonstrated for
the Lynx proteins Lynx1 and Ly6H (Nichols et al. 2014;
Puddifoot et al. 2015). Lypd6 protein is primarily intracel-
lular when over-expressed in COS-7 cells (Zhang et al.
2010), which is in line with a potential intracellular function
of Lypd6 after transgenic expression. We demonstrate that
endogenous Lypd6 is predominantly located on the cell
surface in the rat HIP, whereas this localization is not as
pronounced in the FC. Given the potential opposing function
of surface versus intracellular Lypd6, this differential sub-
cellular distribution of Lypd6 may have a significant impact
on the function of Lypd6 in different brain regions.
Nicotine regulates hippocampal Lypd6 levels
Since nicotine and Lypd6 both affect nAChR function as
well as early development, we found it pertinent to examine
whether exposure to nicotine during development affected
Lypd6 protein levels in the brain. Using an exposure
paradigm known to result in stable plasma levels of nicotine
corresponding to that found in light to moderate smokers
(Matta et al. 2007), we found that perinatal nicotine
exposure to dams produced an almost twofold increase of
Lypd6 in the HIP of the adult offspring, whereas there were
no effects on the Lynx proteins Lynx1 and Ly6H. This
suggests that nicotine has long-term effects on Lypd6
expression.
Maternal smoking during or after pregnancy can have
long-term detrimental effects on the development of the
offspring and lead to lifelong impairments (Blood-Siegfried
and Rende 2010; Abbott and Winzer-Serhan 2012; Clifford
et al. 2012). Pre-natal nicotine exposure reduces hippocam-
pal levels of phosphorylated ERK in rats, and this has been
suggested to underlie the cognitive deficits observed after
gestational nicotine exposure (Parameshwaran et al. 2013).
We find that Lypd6 inhibits nAChR-mediated ERK phos-
phorylation in vitro and that perinatal nicotine administration
increases Lypd6 levels, suggesting that decreased ERK
phosphorylation after pre-natal nicotine administration may
be caused by increased inhibition of nAChRs by Lypd6. It is
therefore possible that part of the detrimental effect of
nicotine on the development of the offspring is because of
dysregulation of Lypd6.
We further showed that the increase in Lypd6 following
nicotine exposure was primarily evident in a putative
nuclear/endosomal fraction, but not in synaptosomes, sug-
gesting that nicotine leads to a preferential increase in non-
synaptic Lypd6. If Lypd6 is able to chaperone nAChRs,
nicotine administration might therefore alter this chaperon-
ing. The effect of nicotine on Lypd6 levels was not
recapitulated by nicotine administration to young or adult
rats, suggesting that Lypd6 is more susceptible to regulation
by nicotine during early development.
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Nicotine administration up-regulates nAChRs in the brain,
including the a3b4 subtype (Govind et al. 2009; Mazzo
et al. 2013). We therefore hypothesized that the effect of
nicotine exposure on Lypd6 protein levels was an indirect
effect caused by up-regulation of nAChRs. However, genetic
ablation of b2-, b4-, or a7-containing nAChRs did not affect
Lypd6 levels, suggesting that decreasing the levels of the
major nAChR subtypes in the brain does not affect Lypd6
protein levels. It is, however, shown that Lynx1 interacts
preferentially with a4/a4 dimers in a4b2 nAChRs (Nichols
et al. 2014), and if Lypd6 preferentially binds to a/a
interfaces as well, we cannot exclude a potential effect of
nicotine via a-subunit up-regulation, other than a7. In a
further attempt to see whether cholinergic tone or physio-
logical changes affected Lypd6 signaling, we investigated
regulation of Lypd6 by environmental enrichment in mice as
well as by acute or repeated exercise training (Fig. S1).
Lypd6 levels were unchanged in these paradigms, suggesting
at least some selectivity in the effect of nicotine on Lypd6
levels. Together with a lack of effect of knockout of nAChR
subunits on Lypd6 levels, these data suggest that the effect of
nicotine on Lypd6 is not dependent on nAChR levels or
cholinergic tone in adult animals. It thus seems that the
regulation of Lypd6 by nicotine is limited to a certain time
window during early development.
Wnt/b-catenin signaling is not only important for early
development but also regulates nAChR localization and
synaptic plasticity in the adult C. elegans nervous system
(Jensen et al. 2012). Since both nicotine and Lypd6 protein
can regulate the Wnt/b-catenin pathway (Zhou et al. 2013;
€Ozhan et al. 2013), it is possible that nicotine affects Lypd6
levels via the Wnt/b-catenin pathway.
In summary, our results indicate that Lypd6 is an
endogenous orthosteric antagonist of cholinergic signaling
in the brain, and that it is dysregulated by nicotine exposure
during early development. This suggests that part of the
detrimental consequences of maternal nicotine exposure
during and after gestation on development of the offspring
may be because of dysregulation of Lypd6 levels.
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